Epigenetic regulation of protein tyrosine phosphatases: potential molecular targets for cancer therapy (original) (raw)

• Bird A . DNA methylation patterns and epigenetic memory. Genes Dev. 2002;16:6–21.
  Article CAS PubMed Google Scholar
• Jones PA, Baylin SB . The fundamental role of epigenetic events in cancer. Nat Rev Genet. 2002;3:415–428.
  Article CAS PubMed Google Scholar
• Feinberg AP, Tycko B . The history of cancer epigenetics. Nat Rev Cancer. 2004;4:143–153.
  Article CAS PubMed Google Scholar
• Wade PA, Gegonne A, Jones PL, et al. Mi-2 complex couples DNA methylation to chromatin remodelling and histone deacetylation. Nat Genet. 1999;23:62–66.
  Article CAS PubMed Google Scholar
• Wade PA, Jones PL, Vermaak D, et al. A multiple subunit Mi-2 histone deacetylase from Xenopus laevis cofractionates with an associated Snf2 superfamily ATPase. Curr Biol. 1998;8:843–846.
  Article CAS PubMed Google Scholar
• Zhang Y, Ng HH, Erdjument-Bromage H, et al. Analysis of the NuRD subunits reveals a histone deacetylase core complex and a connection with DNA methylation. Genes Dev. 1999;13:1924–1935.
  Article CAS PubMed PubMed Central Google Scholar
• Sakai H, Urano T, Ookata K, et al. MBD3 and HDAC1, two components of the NuRD complex, are localized at Aurora-A-positive centrosomes in M phase. J Biol Chem. 2002;277:48714–48723.
  Article CAS PubMed Google Scholar
• Costello JF, Fruhwald MC, Smiraglia DJ, et al. Aberrant CpG-island methylation has non-random and tumour-type-specific patterns [see comments]. Nat Genet. 2000;24:132–138.
  Article CAS PubMed Google Scholar
• Baylin SB, Herman JG, Graff JR, et al. Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res. 1998;72:141–196.
  Article CAS PubMed Google Scholar
• Jones PA, Laird PW . Cancer epigenetics comes of age. Nat Genet. 1999;21:163–167.
  Article CAS PubMed Google Scholar
• Sakai T, Toguchida J, Ohtani N, et al. Allele-specific hypermethylation of the retinoblastoma tumor-suppressor gene. Am J Hum Genet. 1991;48:880–888.
  CAS PubMed PubMed Central Google Scholar
• Myohanen SK, Baylin SB, Herman JG . Hypermethylation can selectively silence individual p16ink4A alleles in neoplasia. Cancer Res. 1998;58:591–593.
  CAS PubMed Google Scholar
• Batova A, Diccianni MB, Yu JC, et al. Frequent and selective methylation of p15 and deletion of both p15 and p16 in T-cell acute lymphoblastic leukemia. Cancer Res. 1997;57:832–836.
  CAS PubMed Google Scholar
• Esteller M, Fraga MF, Guo M, et al. DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis. Hum Mol Genet. 2001;10:3001–3007.
  Article CAS PubMed Google Scholar
• Herman JG, Baylin SB . Gene silencing in cancer in association with promoter hypermethylation. [see comment]. N Engl J Med. 2003;349:2042–2054.
  Article CAS PubMed Google Scholar
• Baylin SB, Herman JG . DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet. 2000;16:168–174.
  Article CAS PubMed Google Scholar
• El-Osta A . The rise and fall of genomic methylation in cancer. Leukemia. 2004;18:233–237.
  Article CAS PubMed Google Scholar
• Hunter T . Signaling — 2000 and beyond. Cell. 2000;100:113–127.
  Article CAS PubMed Google Scholar
• Fischer EH . Cell signaling by protein tyrosine phosphorylation. Adv Enzyme Regul. 1999;39:359–369.
  Article CAS PubMed Google Scholar
• Maroun CR, Naujokas MA, Holgado-Madruga M, et al. The tyrosine phosphatase SHP-2 is required for sustained activation of extracellular signal-regulated kinase and epithelial morphogenesis downstream from the met receptor tyrosine kinase. Mol Cell Biol. 2000;20:8513–8525.
  Article CAS PubMed PubMed Central Google Scholar
• Meng TC, Fukada T, Tonks NK . Reversible oxidation and inactivation of protein tyrosine phosphatases in vivo. Mol Cell. 2002;9:387–399.
  Article CAS PubMed Google Scholar
• Palka HL, Park M, Tonks NK . Hepatocyte growth factor receptor tyrosine kinase met is a substrate of the receptor protein-tyrosine phosphatase DEP-1. J Biol Chem. 2003;278:5728–5735.
  Article CAS PubMed Google Scholar
• Hermiston ML, Xu Z, Majeti R, et al. Reciprocal regulation of lymphocyte activation by tyrosine kinases and phosphatases. J Clin Invest. 2002;109:9–14.
  Article CAS PubMed PubMed Central Google Scholar
• Gupta S, Radha V, Sudhakar C, et al. A nuclear protein tyrosine phosphatase activates p53 and induces caspase-1-dependent apoptosis. FEBS Lett. 2002;532:61–66.
  Article CAS PubMed Google Scholar
• Salmeen A, Andersen JN, Myers MP, et al. Molecular basis for the dephosphorylation of the activation segment of the insulin receptor by protein tyrosine phosphatase 1B. Mol Cell. 2000;6:1401–1412.
  Article CAS PubMed Google Scholar
• Alonso A, Sasin J, Bottini N, et al. Protein tyrosine phosphatases in the human genome. Cell. 2004;117:699–711.
  Article CAS PubMed Google Scholar
• Panagopoulos I, Pandis N, Thelin S, et al. The FHIT and PTPRG genes are deleted in benign proliferative breast disease associated with familial breast cancer and cytogenetic rearrangements of chromosome band 3p14. Cancer Res. 1996;56:4871–4875.
  CAS PubMed Google Scholar
• Zhang Y, Siebert R, Matthiesen P, et al. Cytogenetical assignment and physical mapping of the human R-PTP-kappa gene (PTPRK) to the putative tumor suppressor gene region 6q22.2–q22.3. Genomics. 1998;51:309–311.
  Article CAS PubMed Google Scholar
• Ruivenkamp CA, van Wezel T, Zanon C, et al. Ptprj is a candidate for the mouse colon-cancer susceptibility locus Scc1 and is frequently deleted in human cancers. Nat Genet. 2002;31:295–300.
  Article CAS PubMed Google Scholar
• Wang Z, Shen D, Parsons DW, et al. Mutational analysis of the tyrosine phosphatome in colorectal cancers. Science. 2004;304:1164–1166.
  Article CAS PubMed Google Scholar
• Andersen JN, Jansen PG, Echwald SM, et al. A genomic perspective on protein tyrosine phosphatases: gene structure, pseudogenes, and genetic disease linkage. FASEB J. 2004;18:8–30.
  Article CAS PubMed Google Scholar
• Ardini E, Agresti R, Tagliabue E, et al. Expression of protein tyrosine phosphatase alpha (RPTPalpha) in human breast cancer correlates with low tumor grade, and inhibits tumor cell growth in vitro and in vivo. Oncogene. 2000;19:4979–4987.
  Article CAS PubMed Google Scholar
• Motiwala T, Ghoshal K, Das A, et al. Suppression of the protein tyrosine phosphatase receptor type O gene (PTPRO) by methylation in hepatocellular carcinomas. Oncogene. 2003;22:6319–6331.
  Article CAS PubMed PubMed Central Google Scholar
• Motiwala T, Kutay H, Ghoshal K, et al. Protein tyrosine phosphatase receptor-type O (PTPRO) exhibits characteristics of a candidate tumor suppressor in human lung cancer. Proc Natl Acad Sci USA. 2004;101:13844–13849 Epub 12004 Sep 13848.
  Article CAS PubMed PubMed Central Google Scholar
• Imreh S, Klein G, Zabarovsky ER . Search for unknown tumor-antagonizing genes. Genes, Chromosomes Cancer. 2003;38:307–321.
  Article CAS PubMed Google Scholar
• Mori Y, Yin J, Sato F, et al. Identification of genes uniquely involved in frequent microsatellite instability colon carcinogenesis by expression profiling combined with epigenetic scanning. Cancer Res. 2004;64:2434–2438.
  Article CAS PubMed Google Scholar
• Oka T, Ouchida M, Koyama M, et al. Gene silencing of the tyrosine phosphatase SHP1 gene by aberrant methylation in leukemias/lymphomas. Cancer Res. 2002;62:6390–6394.
  CAS PubMed Google Scholar
• Amoui M, Baylink DJ, Tillman JB, et al. Expression of a structurally unique osteoclastic protein-tyrosine phosphatase is driven by an alternative intronic, cell type-specific promoter. J Biol Chem. 2003;278:44273–44280.
  Article CAS PubMed Google Scholar
• Mancini DN, Singh SM, Archer TK, et al. Site-specific DNA methylation in the neurofibromatosis (NF1) promoter interferes with binding of CREB and SP1 transcription factors. Oncogene. 1999;18:4108–4119.
  Article CAS PubMed Google Scholar
• DiNardo DN, Butcher DT, Robinson DP, et al. Functional analysis of CpG methylation in the BRCA1 promoter region. Oncogene. 2001;20:5331–5340.
  Article CAS PubMed Google Scholar
• Santoro R, Grummt I . Molecular mechanisms mediating methylation-dependent silencing of ribosomal gene transcription. Mol Cell. 2001;8:719–725.
  Article CAS PubMed Google Scholar
• Jenuwein T, Allis CD . Translating the histone code. Science. 2001;293:1074–1080.
  Article CAS PubMed Google Scholar
• Kass SU, Wolffe AP . DNA methylation, nucleosomes and the inheritance of chromatin structure and function. Novartis Found Symp. 1998;214:22–35; discussion 36–50.
  CAS PubMed Google Scholar
• Ghoshal K, Majumder S, Datta J, et al. Role of human ribosomal RNA (rRNA) promoter methylation and of methyl-CpG-binding protein MBD2 in the suppression of rRNA gene expression. J Biol Chem. 2004;279:6783–6793.
  Article CAS PubMed Google Scholar
• Taylor SM, Jones PA . Multiple new phenotypes induced in 10T1/2 and 3T3 cells treated with 5-azacytidine. Cell. 1979;17:771–779.
  Article CAS PubMed Google Scholar
• Baylin SB . Reversal of gene silencing as a therapeutic target for cancer — roles for DNA methylation and its interdigitation with chromatin. Novartis Found Symp. 2004;259:226–233; discussion 234–227.
  CAS PubMed Google Scholar
• Karpf AR, Jones DA . Reactivating the expression of methylation silenced genes in human cancer. Oncogene. 2002;21:5496–5503.
  Article CAS PubMed Google Scholar
• Jain PK . Epigenetics: the role of methylation in the mechanism of action of tumor suppressor genes. Ann NY Acad Sci. 2003;983:71–83.
  Article CAS PubMed Google Scholar
• Majumder S, Ghoshal K, Datta J, et al. Role of de novo DNA methyltransferases and methyl CpG-binding proteins in gene silencing in a rat hepatoma. J Biol Chem. 2002;277:16048–16058.
  Article CAS PubMed Google Scholar
• Ghoshal K, Majumder S, Li Z, et al. Suppression of metallothionein gene expression in a rat hepatoma because of promoter-specific DNA methylation. J Biol Chem. 2000;275:539–547.
  Article CAS PubMed Google Scholar
• Creusot F, Acs G, Christman JK . Inhibition of DNA methyltransferase and induction of Friend erythroleukemia cell differentiation by 5-azacytidine and 5-aza-2′-deoxycytidine. J Biolog Chem. 1982;257:2041–2048.
  CAS Google Scholar
• Christman JK . 5-Azacytidine and 5-aza-2′-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene. 2002;21:5483–5495.
  Article CAS PubMed Google Scholar
• Claus R, Lubbert M . Epigenetic targets in hematopoietic malignancies. Oncogene. 2003;22:6489–6496.
  Article CAS PubMed Google Scholar
• Jones PA, Taylor SM, Wilson VL . Inhibition of DNA methylation by 5-azacytidine. Rec Results Cancer Res. 1983;84:202–211.
  CAS Google Scholar
• Jeltsch A . Beyond Watson and Crick: DNA methylation and molecular enzymology of DNA methyltransferases [erratum appears in Chembiochem 2002 May 3;3(5):382]. Chembiochem:3:274–293.
  Article CAS PubMed Google Scholar
• Bestor TH . The DNA methyltransferases of mammals. Humn Mol Genet. 2000;9:2395–2402.
  Article CAS Google Scholar
• Gius D, Cui H, Bradbury CM, et al. Distinct effects on gene expression of chemical and genetic manipulation of the cancer epigenome revealed by a multimodality approach. Cancer Cell. 2004;6:361–371.
  Article CAS PubMed Google Scholar
• Ghoshal K, Datta J, Majumder S, et al. Inhibitors of histone deacetylase and DNA methyltransferase synergistically activate the methylated metallothionein I promoter by activating the transcription factor MTF-1 and forming an open chromatin structure. Mol Cell Biol. 2002;22:8302–8319.
  Article CAS PubMed PubMed Central Google Scholar
• Suzuki H, Gabrielson E, Chen W, et al. A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. [see comment]. Nat Genet. 2002;31:141–149.
  Article CAS PubMed Google Scholar
• Grunstein M . Histone acetylation in chromatin structure and transcription. Nature. 1997;389:349–352.
  Article CAS PubMed Google Scholar
• Lachner M, Jenuwein T . The many faces of histone lysine methylation. Curr Opin Cell Biol. 2002;14:286–298.
  Article CAS PubMed Google Scholar
• de Ruijter AJ, van Gennip AH, Caron HN, et al. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J. 2003;370:737–749.
  Article CAS PubMed PubMed Central Google Scholar
• Belinsky SA, Klinge DM, Stidley CA, et al. Inhibition of DNA methylation and histone deacetylation prevents murine lung cancer. Cancer Res. 2003;63:7089–7093.
  CAS PubMed Google Scholar
• Shaker S, Bernstein M, Momparler RL . Antineoplastic action of 5-aza-2′-deoxycytidine (Dacogen) and depsipeptide on Raji lymphoma cells. Oncol Rep. 2004;11:1253–1256.
  CAS PubMed Google Scholar
• Kouraklis G, Theocharis S . Histone deacetylase inhibitors and anticancer therapy. Curr Med Chem — Anti-Cancer Agents. 2002;2:477–484.
  Article CAS PubMed Google Scholar
• Cameron EE, Bachman KE, Myohanen S, et al. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet. 1999;21:103–107.
  Article CAS PubMed Google Scholar
• Wharram BL, Goyal M, Gillespie PJ, et al. Altered podocyte structure in GLEPP1 (Ptpro)-deficient mice associated with hypertension and low glomerular filtration rate. J Clin Invest. 2000;106:1281–1290.
  Article CAS PubMed PubMed Central Google Scholar
• Xu GL, Bestor TH, Bourc”his D, et al. Chromosome instability and immunodeficiency syndrome caused by mutations in a DNA methyltransferase gene. Nature. 1999;402:187–191.
  Article CAS PubMed Google Scholar
• Pogribny IP, Miller BJ, James SJ . Alterations in hepatic p53 gene methylation patterns during tumor progression with folate/methyl deficiency in the rat. Cancer Lett. 1997;115:31–38.
  Article CAS PubMed Google Scholar
• Baylin S, Bestor TH . Altered methylation patterns in cancer cell genomes: cause or consequence? Cancer Cell. 2002;1:299–305.
  Article CAS PubMed Google Scholar